ES2730398T3 - Composiciones y procedimientos de visualización del vítreo - Google Patents

Composiciones y procedimientos de visualización del vítreo Download PDF

Info

Publication number
ES2730398T3
ES2730398T3 ES15736046T ES15736046T ES2730398T3 ES 2730398 T3 ES2730398 T3 ES 2730398T3 ES 15736046 T ES15736046 T ES 15736046T ES 15736046 T ES15736046 T ES 15736046T ES 2730398 T3 ES2730398 T3 ES 2730398T3
Authority
ES
Spain
Prior art keywords
seq
composition
vitreous
eye
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES15736046T
Other languages
English (en)
Spanish (es)
Inventor
Joy Ghosh
Thaddeus Peter Dryja
Michael Roguska
Eric Carlson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2730398T3 publication Critical patent/ES2730398T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043—Fluorescein, used in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0076—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion
    • A61K49/0084—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form dispersion, suspension, e.g. particles in a liquid, colloid, emulsion liposome, i.e. bilayered vesicular structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0063—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres
    • A61K49/0069—Preparation for luminescence or biological staining characterised by a special physical or galenical form, e.g. emulsions, microspheres the agent being in a particular physical galenical form
    • A61K49/0089—Particulate, powder, adsorbate, bead, sphere
    • A61K49/0091—Microparticle, microcapsule, microbubble, microsphere, microbead, i.e. having a size or diameter higher or equal to 1 micrometer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4718—Cytokine-induced proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Materials For Medical Uses (AREA)
ES15736046T 2014-06-25 2015-06-24 Composiciones y procedimientos de visualización del vítreo Active ES2730398T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462016731P 2014-06-25 2014-06-25
PCT/IB2015/054747 WO2015198245A1 (en) 2014-06-25 2015-06-24 Compositions and methods for visualization of the vitreous

Publications (1)

Publication Number Publication Date
ES2730398T3 true ES2730398T3 (es) 2019-11-11

Family

ID=53539753

Family Applications (1)

Application Number Title Priority Date Filing Date
ES15736046T Active ES2730398T3 (es) 2014-06-25 2015-06-24 Composiciones y procedimientos de visualización del vítreo

Country Status (8)

Country Link
US (1) US10537648B2 (https=)
EP (1) EP3160512B1 (https=)
JP (2) JP6296581B2 (https=)
CN (1) CN107206107A (https=)
AU (1) AU2015278744B2 (https=)
CA (1) CA2953682A1 (https=)
ES (1) ES2730398T3 (https=)
WO (1) WO2015198245A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025242919A1 (en) * 2024-05-24 2025-11-27 Navigo Proteins Gmbh Novel binding proteins for hyaluronic acid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1733744A1 (en) 2005-06-17 2006-12-20 Ludwig-Maximilians-Universität München Method, dye and medicament for staining the internal limiting membrane and/or the capsule of an eye
JP4936508B2 (ja) * 2006-01-23 2012-05-23 独立行政法人国立国際医療研究センター 蛍光ナノ粒子を含む眼の硝子体染色剤及び染色方法
HUE026001T2 (en) * 2007-02-05 2016-04-28 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of the inflammatory condition of the respiratory system
US20110236310A1 (en) 2008-12-25 2011-09-29 Canon Kabushiki Kaisha Labeling composition for intraocular tissue, labeling method of intraocular tissue, and screening method
US8759298B2 (en) 2010-05-03 2014-06-24 Scott & White Healthcare Protein therapy for corneal inflammation, epithelial wound healing, and photoreceptor degeneration
WO2012135432A2 (en) 2011-03-29 2012-10-04 Kemin Industries, Inc. Dyes for membranes and biological structures
JP6162707B2 (ja) * 2011-10-24 2017-07-12 ハロザイム インコーポレイテッド 抗ヒアルロナン剤治療のためのコンパニオン診断およびその使用方法
EP3838293A1 (en) * 2012-07-11 2021-06-23 Tissuetech, Inc. Compositions containing hc-ha/ptx3 complexes and methods of use thereof
TW201427989A (zh) 2012-12-18 2014-07-16 Novartis Ag 長效性蛋白質之組合物及方法
GB201400994D0 (en) * 2014-01-21 2014-03-05 Ucl Business Plc Drug delivery system

Also Published As

Publication number Publication date
US20170202981A1 (en) 2017-07-20
CA2953682A1 (en) 2015-12-30
US10537648B2 (en) 2020-01-21
WO2015198245A1 (en) 2015-12-30
JP2017524679A (ja) 2017-08-31
EP3160512A1 (en) 2017-05-03
CN107206107A (zh) 2017-09-26
AU2015278744A1 (en) 2017-01-12
JP2018039847A (ja) 2018-03-15
JP6296581B2 (ja) 2018-03-20
EP3160512B1 (en) 2019-05-22
AU2015278744B2 (en) 2018-09-27

Similar Documents

Publication Publication Date Title
ES2708181T3 (es) Inhibidores de agregación de alfa-cristalina para el tratamiento de catarata
ES2730972T3 (es) Estructura cristalina de sortilina humana y sus usos para identificar ligandos de sortilina
BR112013028914B1 (pt) Uso de um peptídeo inibidor de integrina que consiste em glicinil-arginil-glicinil-cisteico (ácido)-treonil-prolina-cooh para tratar edema macular
US20170173221A1 (en) Self-assembling peptides as bronchial obstruction agents
ES2587828T3 (es) Formulación tópica oftálmica de péptidos
ES2930034T3 (es) Regulación por norrin de proteínas de unión y el uso de las mismas para tratar edema inducido por fuga de la membrana epitelial o endotelial
BRPI0622006A2 (pt) usos de proteìna-veìculo e dìmero de colchicina ou tiocolchicina, forma unitária de dosagem, composição farmacêutica e kits
US20180094137A1 (en) Compositions and methods for the delivery of drugs to the ocular surface by contact lenses
BR112015023348B1 (pt) Composição oftálmica
ES2745291T3 (es) Moléculas difuncionales que contienen PEG para su uso en la inhibición de cataratas y presbicia
Cai et al. Injectable self-assembling peptide hydrogel as a promising vitreous substitute
ES2730398T3 (es) Composiciones y procedimientos de visualización del vítreo
Xu et al. Thermoresponsive gel for sustained release of BMP4 to inhibit corneal neovascularization
ES2609927T3 (es) Composiciones y métodos para tratamientos durante periodos no agudos después de lesiones neurológicas del SNC
CN109640973A (zh) 近视的治疗
US11160881B2 (en) Dendrimer compositions for use in angiography
ES2264416T3 (es) Uso del factor de crecimiento de los nervios para la preparacion de un medicamento para la terapia de patologias de tejidos intraoculares.
ES2971592T3 (es) Composiciones para el tratamiento de enfermedades degenerativas de la retina
EP4522118A2 (en) Chemerin-containing formulation for treating dry eye disease
CN119192407B (zh) 一种多肽-地塞米松偶联物及其制备方法与应用
ES3021225T3 (en) Ligand controling interaction between gags with their effector molecules and use thereof
CN102083411B (zh) 载体
ES2475243T3 (es) Uso del pentap�ptido PHSRN en formulaciones oft�lmicas
ES3034835T3 (en) Monomeric annexin a5 for use in the treatment of macular oedema or retinal vein occlusion
ES2991634T3 (es) Vasodilatadores para su uso en el tratamiento de un trastorno isquémico de la retina